Experiments with a Model Water Tunnel

This report describes a model water tunnel built in 1928 by the NACA to investigate the possibility of using water tunnels for aerodynamic investigations at large scales. The model tunnel is similar to an open-throat wind tunnel, but uses water for the working fluid

The effects of thermal dehydration on performance of the Wingate test of anaerobic power.

Paper copy at Leddy Library: Theses & Major Papers - Basement, West Bldg. / Call Number: Thesis1979 .J336. Source: Masters Abstracts International, Volume: 40-07, page: . Thesis (M.H.K.)--University of Windsor (Canada), 1979

Biosimilars in Oncology: From Development to Clinical Practice

Biologics play an integral role in the treatment of cancer not only for their therapeutic effects and ability to improve outcomes, but also as supportive care agents. Biologics are more complex to manufacture and take longer to bring to market. Because biologics are considerably more costly than small-molecule drugs, their use has placed an increasing economic demand on healthcare systems worldwide. Biosimilars are designed to be highly similar to existing branded biologics, but because biologics cannot be exactly copied, biosimilars should not be referred to as generic, exact versions of the innovator biologic. Biosimilars have the potential to increase access and provide lower cost options for cancer care as patent protection for some of the most widely used biologics begins to expire. Regulatory requirements for biosimilars are evolving, as are global harmonization and/or standardization strategies that can facilitate their robust clinical development. This review highlights critical factors involved with the integration of biosimilars into oncology treatment paradigms and practices. Clinicians will likely seek out practice guidelines and position statements from established scientific societies to help evaluate key information regarding biosimilars, such as efficacy, safety, comparability, and interchangeability with the reference biologic. Automatic substitution, nomenclature, extrapolation of clinical data from one indication to another, as well as parameters for ongoing pharmacovigilance are evolving considerations. Education of physicians and other healthcare providers, payers, and patients about biosimilars may facilitate informed decision making, promote acceptance of biosimilars into clinical practice, increase accessibility, and expedite associated health and economic benefits

Airfoil section data obtained in the NACA variable-density tunnel as affected by support interference and other corrections

The results of an investigation of the effect of support interference on airfoil drag data obtained in the variable-density tunnel are presented. As a result of the support interference, previously published airfoil data from the variable-density tunnel have shown too large drag coefficients and too large a rate of increase of drag coefficients and too large a rate increase of drag coefficients with airfoil thickness. The practical effect of the corrections on the choice of the optimum section is briefly considered and corrected data for a selected list of airfoils are presented as a convenience to the designer. Methods of correcting published data for other airfoils are presented

Biosimilars and cancer treatment of older patients

AbstractBiosimilar monoclonal antibodies are being developed globally to meet clinical demand in oncology and potentially provide greater access to biologic therapies for patients with cancer, including older patients. In this supplement, we present an overview of the development, approval requirements, and characteristics of biosimilar monoclonal antibodies that may help practicing oncologists and other healthcare providers to acquire familiarity with this new group of therapeutic biologic agents. Furthermore, we review and discuss some of the challenges and potential strategies for the management of older patients with cancer, who represent an increasing population in many countries

Preliminary Investigation of Certain Laminar-Flow Airfoils for Application at High Speeds and Reynolds Numbers

In order to extend the useful range of Reynolds numbers of airfoils designed to take advantage of the extensive laminar boundary layers possible in an air stream of low turbulence, tests were made of the NACA 2412-34 and 1412-34 sections in the NACA low-turbulence tunnel. Although the possible extent of the laminar boundary layer on these airfoils is not so great as for specially designed laminar-flow airfoils, it is greater than that for conventional airfoils, and is sufficiently extensive so that at Reynolds numbers above 11,000,000 the laminar region is expected to be limited by the permissible 'Reynolds number run' and not by laminar separation as is the case with conventional airfoils. Drag measurements by the wake-survey method and pressure-distribution measurements were made at several lift coefficients through a range of Reynolds numbers up to 11,400,000. The drag scale-effect curve for the NACA 1412-34 is extrapolated to a Reynolds number of 30,000,000 on the basis of theoretical calculations of the skin friction. Comparable skin-friction calculations were made for the NACA 23012. The results indicate that, for certain applications at moderate values of the Reynolds number, the NACA 1412-34 and 2412-34 airfoils offer some advantages over such conventional airfoils as the NACA 23012. The possibility of maintaining a more extensive laminar boundary layer on these airfoils should result in a small drag reduction, and the absence of pressure peaks allows higher speeds to be reached before the compressibility burble is encountered. At lower Reynold numbers, below about 10,000,000, these airfoils have higher drags than airfoils designed to operate with very extensive laminar boundary layers

Investigation of Extreme Leading-Edge Roughness on Thick Low-Drag Airfoils to Indicate Those Critical to Separation

Several airfoils, Including a conventional NACA 23021 and some low-drag airfoils for which the thickness had been increased to the point that they were considered doubtfully conservative with respect to separation, were investigated as smooth airfoils and after the application of a standard roughness. The results show some of the airfoils to be critical to separation resulting from such flow disturbances. It is concluded, pending the further investigation of separation difficulties, that airfoil sections falling definitely within the conservative range should be used

TEOS: A framework for constructing operational definitions of medication adherence based on Timelines – Events – Objectives – Sources

Objectives: Managing adherence to medications is a priority for health systems worldwide. Adherence research is accumulating, yet the quality of the evidence is reduced by various methodological limitations. In particular, the heterogeneity and low accuracy of adherence measures have been highlighted in many literature reviews. Recent consensus-based guidelines advise on best practices in defining adherence (ABC) and reporting of empirical studies (EMERGE). While these guidelines highlight the importance of operational definitions in adherence measurement; such definitions are rarely included in study reports. To support researchers in their measurement decisions, we developed a structured approach to formulate operational definitions of adherence. Methods: A group of adherence and research methodology experts used theoretical, methodological and practical considerations to examine the process of applying adherence definitions to various research settings, questions and data sources. Consensus was reached through iterative reviewing of discussion summaries and framework versions. Results: We introduce TEOS, a four-component framework to guide the operationalization of adherence concepts: 1) describe treatment as four simultaneous interdependent timelines (recommended and actual use, conditional on prescribing and dispensing); 2) locate four key events along these timelines to delimit the three ABC phases (first and last recommended use, first and last actual use); 3) revisit study objectives and design to finetune research questions and assess measurement validity and reliability needs, and 4) select data sources (e.g., electronic monitoring, self-report, electronic healthcare databases) that best address measurement needs. Conclusion: Using the TEOS framework when designing research and reporting explicitly on these components can improve measurement quality